Q-omics provides the consensus-scored YPEL2 profile across patient tissues and cancer cell-line models. YPEL2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, YPEL2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, YPEL2 RNA expression shows 21,030 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where YPEL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YPEL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YPEL2 survival associations across molecular data types. YPEL2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YPEL2 RNA expression–survival associations across cancer types. High YPEL2 expression shows unfavorable associations in UCEC and READ, but favorable associations in KIRC, LUAD, SARC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for YPEL2 RNA expression.
This table summarizes YPEL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for YPEL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YPEL2 shows lower tumor expression in KICH, UCEC, LUAD, LUSC and COAD and higher tumor expression in KIRC. The KIRC box plot shows higher YPEL2 RNA expression in tumor versus normal tissue (log2 FC = +1.229, t-test p < 0.001).
This table shows molecular features associated with YPEL2 in patient tissues and cancer cell lines. In patient samples, YPEL2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, YPEL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
